| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2b data readout example | VLS-01 (DMT buccal film) treatment-resistant depression (TRD) | Phase 2b | — | Peptides | Psychiatric Disorders | ||
phase 2b data readout example | VLS-01 (DMT buccal film) treatment-resistant depression (TRD) | Phase 2b | — | Peptides | Psychiatric Disorders | ||
phase 2b data readout example | VLS-01 (DMT buccal film) treatment-resistant depression (TRD) | Phase 2b | — | Peptides | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
AtaiBeckley Inc.$4.88
-0.39 (-7.4%)
D 36Pipeline Score Richly Valued Pharma · Commercial
Market Cap
1.77 B
EPS
-2.24
P/E Ratio
-2.15 $
Value Trade
22.25 M
SEC Financials
Q1 2026Dilution Risk
Revenue
954.00 K
R&D Expenses
600.00 K
Operating CF
-21.09 M
Total Assets
264.88 M
Total Liabilities
66.10 M
Equity
198.68 M
D/E Ratio
12,345
8.27 %
Week
-12.9 %
1 Month
12.79 %
3 Month
18.36 %
6 Month
-79.43 %
5 Year
-79.43 %
All Time
Cash Data
Cash Position
43.10 M
Monthly Burn
7.03 M
Runway
4.6 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
8.20 M
52 Week Range
2 - 6.75
% held by Insiders
20.1 %
% held by Institutions
26.1 %
Enterprise Value
1.54 B
Total Shares
366.92 M
Short %
8.01 %
Float Shares
298.67 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AtaiBeckley Inc.
61Total events
6Upcoming
23Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 6
Event history 55
Jun 29, 2026
Jun 15, 2026
◆Oral PresentationPresentation
7th Annual HCW Neuro Perspectives Hybrid Conference Virtual Presentation
Jun 10, 2026
Jun 3, 2026
Apr 22, 2026
▲Full ResultsEMP-01Clinical Data
Additional Phase 2a results for EMP-01 showing large improvements in SAD
Social Anxiety Disordersource ↗
Apr 16, 2026
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
Apr 14, 2026
▲End Of Phase 2 MeetingBPL-003FDA Meeting
Successful End-of-Phase 2 meeting with FDA for BPL-003
treatment-resistant depressionsource ↗
Apr 8, 2026
▲Full ResultsBPL-003Clinical Data
Phase 2a results published in CNS Drugs showing rapid and durable antidepressant response
treatment-resistant depressionsource ↗
Q2 2026
◆Trial InitiationBPL-003Trial
Phase 3 clinical trial initiation expected in Q2 2026
treatment-resistant depressionsource ↗
Drug Pipeline Intelligence
D36
Pipeline Score $186M
Pipeline ValueRichly Valued
Valuation Signal10
Drugs Scored0.1x
rNPV / MCap Top 50%
Micro Cap (rank 453 of 905)
Percentile RankAtaiBeckley Inc. faces pipeline headwinds (36/100), with $1.1B risk-adjusted pipeline value, led by RL-007 in Cognitive Impairment (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RL-007 Small molecule | Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | NCT05686239 | 24% | $212M | COMPLETED | 242 | - | - | Apr 9, 2025 | - | Jul 30, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EMP-01 | Social Anxiety Disorder | 2a | 2026-02-26 | |||
EMP-01 | Social Anxiety Disorder | 2a | 2026-02-26 | |||
EMP-01 | Social Anxiety Disorder | 2a | 2026-02-26 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ATAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATAI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATAI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ATAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATAIAtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
AtaiBeckley Inc. has announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective June 29, 2026. This addition is expected to enhance the company's visibility in U.S. equity markets, following its recent inclusion in other major indices. The CEO emphasized the significance of this milestone as the company progresses with its Phase 3 study of BPL-003.
Read more →ATAIAtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
AtaiBeckley Inc. has introduced a Patient Impact Grant Program, offering three $20,000 grants aimed at supporting non-profit organizations that enhance mental health outcomes. The program is designed to foster community support, reduce stigma, and stimulate innovative research within the mental health ecosystem. Applications are currently open and will close on September 1st, with selected recipients evaluated by a panel of experts in the field.
Read more →ATAIAtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
AtaiBeckley Inc. will participate in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Oppenheimer CNS and Neuro-Muscular Summit. The company aims to showcase its innovative mental health treatments, which are currently in various stages of clinical development. Live webcasts of the presentations will be available on their investor website.
Read more →ATAIAtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
AtaiBeckley Inc. reported its Q1 2026 financial results and provided updates on its clinical pipeline. The company is set to initiate the Phase 3 program for BPL-003 in treatment-resistant depression in Q2 2026, with positive data from EMP-01 in Social Anxiety Disorder. Despite a net loss increase, the company maintains a strong cash position to support its operations through 2029.
Read more →ATAIAtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
AtaiBeckley Inc. has been awarded the Silver Award in the 2026 Patient Participant Index for its collaboration with PsyPAN, emphasizing the importance of participant insights in psychedelic clinical research. The partnership aims to enhance the ethical development of mental health therapies by integrating lived experiences from trial participants. This recognition showcases the growing significance of patient partnerships in the biopharmaceutical sector.
Read more →ATAIAtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
AtaiBeckley has announced positive Phase 2a results for EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder (SAD). The trial demonstrated significant reductions in patient-reported symptoms and clinician-rated improvements, with 49% of patients reporting noticeable benefits. The treatment was well tolerated, with no severe adverse events noted, suggesting a promising new option for SAD management.
Read more →ATAIAtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
AtaiBeckley Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference and the Needham Virtual Psychedelics Forum. CEO Dr. Srinivas Rao will engage in discussions regarding late-stage clinical development, regulatory considerations, and the commercial potential of its FDA Breakthrough Therapy-designated treatment, BPL-003. This treatment, which is an intranasal formulation of mebufotenin benzoate, is set to enter Phase 3 studies following a successful End-of-Phase 2 FDA meeting. The forums provide an opportunity to showcase AtaiBeckley's progress in transforming mental health therapies.
Read more →ATAIAtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
AtaiBeckley Inc. announced positive Phase 2a results for BPL-003, showing a 66.7% antidepressant response rate by Day 2 in treatment-resistant depression patients. The study demonstrated sustained responses at Week 12, with 83% of participants in the 10 mg cohort maintaining their response. BPL-003, which received FDA Breakthrough Therapy Designation, is set to enter Phase 3 trials in Q2 2026.
Read more →ATAIAtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
AtaiBeckley Inc. has been added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S. benchmark indices, effective March 23, 2026. This inclusion is expected to enhance the company's market presence and attract passive fund investments. The company is advancing its clinical pipeline, with the BPL-003 Phase 3 program set to start in Q2 2026.
Read more →ATAIUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On
Atai Beckley N.V. has completed the acquisition of Beckley Psytech Limited on November 5, 2025. Originally, atai was set to issue 105 million shares to Beckley Psytech's shareholders, but this number was adjusted to approximately 103.8 million shares due to agreed leakages. Following the acquisition, Beckley Psytech and its subsidiaries have become wholly-owned entities of atai. The unaudited pro forma financial information provided reflects the operations for the year ended December 31, 2025, incorporating both atai and Beckley Psytech's financial data.
Read more →ATAIAtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2
AtaiBeckley reported its financial results for Q4 and full year 2025, revealing a significant net loss of $660 million. The company is optimistic about its pivotal Phase 3 program for BPL-003, aimed at treatment-resistant depression, slated to begin in Q2 2026. Positive clinical results were noted for EMP-01 in Social Anxiety Disorder, meeting safety and efficacy goals. Furthermore, AtaiBeckley projects strong financial support through 2029, which is crucial for its ongoing development programs and market positioning in mental health treatments.
Read more →ATAIAtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
AtaiBeckley announced a successful End-of-Phase 2 meeting with the FDA for BPL-003, an intranasal formulation for treatment-resistant depression. The FDA endorsed the proposed Phase 3 program, which includes two pivotal studies aimed at demonstrating efficacy and safety. The company plans to initiate the Phase 3 program in Q2 2026 and will host a Virtual Investor Day to discuss the strategy further.
Read more →ATAIAtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
AtaiBeckley Inc. announced positive topline results from its Phase 2a trial of EMP-01 (oral R-MDMA) for Social Anxiety Disorder. The study met its primary safety objective and showed promising efficacy signals, with significant symptom reduction compared to placebo. The findings suggest that EMP-01 could offer a new treatment avenue for patients with this challenging condition.
Read more →ATAIAtaiBeckley To Host Virtual Investor Day on March 6, 2026
AtaiBeckley Inc. will host a Virtual Investor Day on March 6, 2026, featuring presentations and Q&A sessions with its executive team and external experts. The event aims to engage investors and analysts, showcasing the company's commitment to advancing mental health treatments. A replay will be available post-event on their website.
Read more →ATAIAtaiBeckley Appoints Michael Faerm as Chief Financial Officer NEW YORK, UNITED STATES - FEBRUARY 19, 2026 - AtaiBeckley Inc (NASDAQ: ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mis
AtaiBeckley Inc has appointed Michael Faerm as its new Chief Financial Officer, effective March 9, 2026. Faerm brings over 25 years of experience in financial executive roles within the life sciences sector, which is expected to be instrumental as the company advances its leading therapy, BPL-003, towards Phase 3 trials. Anne Johnson will transition to the role of Chief Accounting Officer, ensuring continuity in financial operations. This strategic appointment aligns with AtaiBeckley's mission to develop innovative mental health treatments.
Read more →ATAIAtaiBeckley To Participate in Upcoming Investor Conferences
AtaiBeckley Inc. announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and Jefferies 2026 Biotech on the Beach. CEO Srinivas Rao and VP Jason Awe will engage in fireside chats and one-on-one meetings to discuss the company's pipeline of mental health treatments. The events will be accessible via live webcasts on the company's investor website.
Read more →ATAIAtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
AtaiBeckley Inc. participated in the 64th Annual ACNP Meeting, presenting significant findings on BPL-003, a nasal spray for treatment-resistant depression. The Phase 2b study results demonstrated rapid and sustained antidepressant effects, leading to its recognition as a Hot Topic. Additionally, preclinical data on 5-MeO-DMT was presented, supporting its potential in treating mood disorders.
Read more →ATAIAtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference NEW YORK, UNITED STATES - 8 JANUARY 2026 - AtaiBeckley Inc (NASDAQ: ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage bio
AtaiBeckley Inc provided an optimistic outlook for 2026 ahead of the J.P. Morgan Healthcare Conference, emphasizing its momentum following the strategic combination of atai Life Sciences and Beckley Psytech. The CEO highlighted the company's potential to impact mental health treatment and its financial stability into 2029. Significant developments in their clinical pipeline, including treatments for depression and anxiety disorders, are set for 2026. AtaiBeckley aims to advance innovative therapies that integrate into healthcare systems.
Read more →ATAIAtaiBeckley Completes Redomiciliation to the United States
AtaiBeckley Inc. has completed its redomiciliation from the Netherlands to the U.S., with the approval of 99% of its shareholders. This transition aims to reduce costs and align more closely with its U.S. market and investors. The company will continue to trade on NASDAQ under the ticker 'ATAI' following an exchange of shares. AtaiBeckley is focused on developing innovative treatments for mental health issues.
Read more →ATAIAtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
Atai Beckley N.V. has announced its addition to the Nasdaq Biotechnology Index, effective December 22, 2025. This milestone reflects the company's progress in developing innovative mental health treatments and strengthening its corporate structure, including a significant funding boost of about $300 million. CEO Srinivas Rao highlighted that 2025 has been a defining year, with several clinical programs advancing towards late-stage development. The company aims to leverage this recognition to enhance long-term value for both patients and shareholders.
Read more →ATAIAtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
AtaiBeckley N.V. has been granted a new U.S. patent for EMP-01, an oral formulation of R-MDMA, which enhances its intellectual property portfolio and provides exclusivity until 2043. This patent covers a stable salt form of the drug, beneficial for formulation and storage. The company aims to address unmet needs in mental health, particularly social anxiety disorder, with upcoming Phase 2a study data expected in early 2026.
Read more →ATAIAtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
Atai Beckley N.V. announced its participation in the Jefferies Global Healthcare Conference in London, featuring a fireside chat with CEO Srinivas Rao and CMO Kevin Craig. The event is scheduled for November 20, 2025, aiming to enhance investor engagement. Atai Beckley is focused on advancing mental health treatments, highlighting its innovative pipeline that includes therapies for treatment-resistant depression and social anxiety disorder. The company aims to integrate its therapies into healthcare systems for better patient outcomes.
Read more →ATAIAtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Atai Beckley N.V. announced its third quarter 2025 financial results, highlighting the FDA's Breakthrough Therapy designation for its drug BPL-003 aimed at treatment-resistant depression. The company reported positive data from Phase 2 trials, indicating strong potential for BPL-003, and scheduled an End-of-Phase 2 meeting with the FDA to discuss further development. Atai Beckley's pipeline also includes EMP-01 for social anxiety disorder and seeks to develop innovative non-hallucinogenic treatments for opioid use disorder, bolstered by a recent public offering of approximately $150 million. The company anticipates funding its operations through 2029 based on current financial resources.
Read more →ATAIAtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
AtaiBeckley reported positive top-line data from a Phase 2b open-label extension study of BPL-003, a treatment for treatment-resistant depression. The study demonstrated that a 12 mg dose administered eight weeks after the initial dose led to additional meaningful antidepressant effects, maintained for up to eight weeks. An End-of-Phase 2 meeting has been scheduled with the FDA to discuss the Phase 3 development plans, which are anticipated to commence in mid-2026. The findings may support a new approach to treatment-resistant depression therapy.
Read more →Competitive Position
How ATAI ranks across every disease it competes inCompetitive Position is a premium feature
See how ATAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial